Angiotensin antagonists such as saralasin and captopril are anticipated to become valuable clinical tools for screening secondary hypertension and treating moderate to severe hypertension.
Answers are grounded in this paper and cite their sources.
May warrant cautious exploration in hypertension screening; leaves open prospective validation before adoption.
The number of studies in the literature on diagnostic and therapeutic uses of angiotensin antagonists has been increasing geometrically. Nearly 1,000 publishsd items deal with saralasin alone, although neither saralasin nor captopril is yet approved for general use or widely available. Reports to date represent only a fraction of the eventual situations in which these agents are likely to help the researcher and clinician. Food and Drug Administration approval of both agents is pending, and both are expected to be available soon. Consequently, the practitioner will want to become familiar with their usefulness, especially to screen for secondary forms of hypertension and to treat moderate to severe primary or secondary hypertension.
No takes yet. Share an insight, caveat, or question.
Zawada et al. (1980) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: